Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

The company made an upfront payment and will provide success-based milestones and royalties in exchange for global rights.

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

As the demand for novel therapies and personalized medicine surges, leaders are uniquely positioned to create a culture of creativity, collaboration and innovation.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...